29 / 62
Neumol Pediatr 2016; 11 (1): 23 - 27
C o n t e n i d o d i s p o n i b l e e n h t t p : / / www. n e umo l o g i a - p e d i a t r i c a . cl
27
Farmacocinética y farmacodinámica de antibióticos utilizados en pacientes pediátricos con fibrosis quística
4.
Khan DD, Lagerbäck P, Cao S, Lustig U, Nielsen EI, Cars O et
al. A mechanism-based pharmacokinetic/pharmacodynamic
model allows prediction of antibiotic killing from MIC values
for WT and mutants. J Antimicrob Chemother 2015; 70:
3051-3060
5.
Sime FB, Roberts MS, Roberts JA. Optimization of dosing
regimens and dosing in special populations. Clin Microbiol
Infect 2015; 21:886-893
6.
Asín-Prieto E, Rodríguez-Gascón A, Isla A. Applications of
the pharmacokinetic/pharmacodynamic (PK/PD) analysis of
antimicrobial agents. J Infect Chemother 2015; 21:319-329
7.
Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL,
Leeder JS, Kauffman RE. Developmental pharmacology-drug
disposition, action, and therapy in infants and children. N
Engl J Med 2003; 349:1157-1167
8.
Saavedra I, Quiñones L, Saavedra M, Sasso J, León J, Roco A.
Pediatric drugs pharmacokinetics. Rev Chil Pediatr 2008;79:
249-258
9.
Kearns GL. Pharmacokinetics in infants and children. Inflamm
Bowel Dis. 1998; 4:104-5
10. Johnson TN, Thomson M. Intestinal metabolism and transport
of drugs in children: the effects of age and disease. J Pediatr
Gastroenterol Nutr 2008; 47: 3-10
11. Salem F, Johnson TN, Barter ZE, Leeder JS, Rostami-Hodjegan
A. Age related changes in fractional elimination pathways
for drugs: assessing the impact of variable ontogeny on
metabolic drug-drug interactions. J Clin Pharmacol 2013;
53:857-65
12. Thomson AH. Individualization of drug dosage--past, present
and future. Med Monatsschr Pharm 2003; 26: 150-152.
13. Zobell J, Waters CD, Young DC, Stockmann C, Ampofo
K, Sherwin C et al. Optimization of Anti-pseudomonal
Antibiotics for Cystic Fibrosis Pulmonary Exacerbations:
II. Cephalosporins and Penicillins. Pediatr Pulmonol 2013;
48:107-122
14. Kercsmar CM, Stern RC, Reed MD, Myers CM, Murdell D,
Blumer JL. Ceftazidime in cystic fibrosis: pharmacokinetics
and therapeutic response. J Antimicrob Chemother 1983;
12:289–295
15. Grenier B, Autret E, Marchand S, Thompson R. Kinetic
parameters of amikacin in cystic fibrosis children. Infection
1987; 15: 295-299
16. The European Committee on Antimicrobial Suceptibility
Testing. Breakpoints tables for interpretation of MICs and
diameters. Version 3.1, EUCAST, (2013)
17. Tsai D, Lipman J, Roberts JA. Pharmacokinetic/
pharmacodynamic considerations for the optimization of
antimicrobial delivery in the critically ill. Curr Opin Crit Care
2015; 21:412-20
18. Langan KM, Kotsimbos T, Peleg AY. Managing Pseudomonas
aeruginosa respiratory infections in cystic fibrosis. Curr Opin
Infect Dis 2015; 28:547-56
19. Pajot O, Burdet C, Couffignal C, Massias L, Armand-Lefevre
L, Foucrier A, Da Silva D, et al. Impact of imipenem and
amikacin pharmacokinetic/pharmacodynamic parameters on
microbiological outcome of Gram-negative bacilli ventilator-
associated pneumonia. J Antimicrob Chemother 2015;
70:1487-1494
20. Young DC, Zobell JT, Stockmann C, Waters CD, Ampofo K,
Sherwin CM, Spigarelli MG. Optimization of anti-pseudomonal
antibiotics for cystic fibrosis pulmonary exacerbations: V.
Aminoglycosides. Pediatr Pulmonol 2013;48:1047-61
21. Contreras AM, Gamba G, Cortés J, Santiago Y, Nares F,
Jimenez-Sanchez G, Bobadilla J, et al. Serial trough and peak
amikacin levels in plasma as predictors of nephrotoxicity.
Antimicrob Agents Chemother. 1989; 33:973-976
22. Raidt L, Idelevich EA, Dübbers A, Küster P, Drevinek P,
Peters G, Kahl BC. Increased Prevalence and Resistance of
Important Pathogens Recovered from Respiratory Specimens
of Cystic Fibrosis Patients During a Decade. Pediatr Infect Dis
J 2015;34:700-5
23. Zobell JT, Epps KL, Young DC, Montague M, Olson J, Ampofo
K, Chin MJ et al . Utilization of Antibiotics for Methicillin-
Resistant Staphylococcus aureus Infection in Cystic Fibrosis.
Pediatr Pulmonol 2015; 552-559
24. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig
W, Billeter M, Dalovisio JR et al. Therapeutic monitoring
of vancomycin in adult patients: a consensus review of
the American Society of Health-System Pharmacists, the
Infectious Diseases Society of America, and the Society of
Infectious Diseases Pharmacists. Am J Health Syst Pharm
2009; 66:82-98
25. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ.
Pharmacodynamics of vancomycin and other antimicrobials
in patients with Staphylococcus aureus lower respiratory
tract infections. Clin Pharmacokinet 2004;43:925-942
26. Hoang J, Dersch-Mills D, Bresee L, Kraft T, Vanderkooi OG.
Achieving therapeutic vancomycin levels in pediatric patients.
Can J Hosp Pharm 2014;67:416-422
27. Stockmann C, Sherwin CM, Zobell JT, Lubsch L, Young
DC, Olson J, Noyes BE, et al. Population pharmacokinetics
of intermittent vancomycin in children with cystic fibrosis.
Pharmacotherapy 2013;33:1288-1296
28. Guillot E, Sermet I, Ferroni A, Chhun S, Pons G, Zahar JR,
Jullien V. Suboptimal ciprofloxacin dosing as a potential
cause of decreased Pseudomonas aeruginosa susceptibility
in children with cystic fibrosis. Pharmacotherapy
2010;30:1252-1258
29. Schaefer HG, Stass H, Wedgwood J, Hampel B, Fischer C,
Kuhlmann J, Schaad UB. Pharmacokinetics of ciprofloxacin
in pediatric cystic fibrosis patients. Antimicrob Agents
Chemother 1996;40:29-34.
30. Stockmann C, Sherwin CM, Zobell JT, Young DC, Waters CD,
Spigarelli MG, Ampofo K. Optimization of anti-pseudomonal
antibiotics for cystic fibrosis pulmonary exacerbations: III.
fluoroquinolones. Pediatr Pulmonol 2013;48:211-220.